Who is sponsoring NCT03623347?

NCT03623347 is sponsored by Centre Hospitalier Universitaire, Amiens.

What drugs are being tested in NCT03623347?

Interventions in NCT03623347: TMZ and BEV induction before chemoradiotherapy.

What condition does NCT03623347 study?

NCT03623347 studies Chemoradiotherapy.

Is NCT03623347 still recruiting?

NCT03623347 is currently completed. Last updated 7 June 2023.

Last reviewed 2023-06-07 · How we verify

NCT03623347: TEMOBEVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Upfront Bevacizumab/témozolomide for Gliomastomas With Neurological Impairment

Completed Last updated 7 June 2023

What this trial tests

trial testing TMZ and BEV induction before chemoradiotherapy in Chemoradiotherapy in 70 participants. Completed in 12 May 2017.

Timeline

1 January 2011

Primary endpoint
12 May 2017

12 May 2017

Quick facts

Lead sponsor	Centre Hospitalier Universitaire, Amiens
Status	Completed
Study type	OBSERVATIONAL
Enrollment	70
Start date	1 January 2011
Primary completion	12 May 2017
Estimated completion	12 May 2017

Drugs / interventions tested

TMZ and BEV induction before chemoradiotherapy

Conditions studied

Chemoradiotherapy — all drugs for Chemoradiotherapy →

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

18 and older, any sex, with Chemoradiotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-basedn chemoradiotherapy. Bevacizumab (BEV), an antiangiogenic anti-VEGF-R monoclonal antibody, has a rapid impact on tumor-related brain edema in recurrent GB. The present study reports the feasibility and efficacy of an induction treatment with TMZ and BEV to alleviate the initial neurological impairment and/or to reduce the tumor volume before a delayed chemoradiotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Medical Management of Cerebral Edema: Past, Present, and Future Therapies.
Halstead MR, Geocadin RG. · · 2019 · cited 56× · PMID 31512062 · DOI 10.1007/s13311-019-00779-4
Angiogenesis in Glioblastoma-Treatment Approaches.
Nowacka A, Śniegocki M, Smuczyński W, Bożiłow D, et al · · 2025 · cited 20× · PMID 40136656 · DOI 10.3390/cells14060407

Verify or expand the search:

Other recruiting trials for Chemoradiotherapy

Currently open trials in the same condition.

NCT07198165 — SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC · Phase 2 · recruiting
NCT07086469 — Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unres · Phase 2 · recruiting
NCT07091305 — A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limite · Phase 2 · active not recruiting
NCT06758830 — Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. · Phase 2, PHASE3 · recruiting
NCT06719700 — Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung · Phase 2 · recruiting

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

NCT07354568 — Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock · recruiting
NCT07071662 — Induction of Labor in Breech Presentation · completed
NCT06909487 — Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respec · completed
NCT07037719 — Automatic Detection of Eligible Patients to RAUC Protocol (RAUCISABLE) · recruiting
NCT06996145 — Study of the Isometry of the Anterior Cruciate Ligament From the Center of the Native MRI Insertion Reported on Dynamic · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03623347 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire, Amiens
Last refreshed: 7 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03623347.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing